Q3 2025 Zealand Pharma A/S Earnings Call Transcript
Key Points
- Zealand Pharma AS (ZLDPF) achieved a key milestone in the Phase 2 Supreme One trial for obesity, with topline data expected in the first half of 2026.
- The company is rapidly approaching data from several Phase 3 trials, including the 76-week Synchronized One trial, with results anticipated in the first half of 2026.
- Zealand Pharma AS (ZLDPF) has a strong partnership with Roche, which is expected to redefine the future of weight management and establish leadership in the obesity therapy market.
- The company has a solid financial position with a cash reserve of 16.2 billion DKK, bolstered by a 9.2 billion DKK upfront payment from Roche.
- Zealand Pharma AS (ZLDPF) is focused on developing therapies that patients can stay on, aiming to address the obesity pandemic by increasing patient adherence and therapy duration.
- The company's third-party manufacturer's facility for dasiglucagon has not received the anticipated classification upgrade, causing delays.
- Zealand Pharma AS (ZLDPF) decided to pause the development of dapiglutide due to the crowded GLP-1 therapeutic space and the high bar for clinical differentiation.
- There are concerns about the tolerability of amylin-based therapies, which could impact patient adherence and acceptance.
- The company faces challenges in harmonizing dose escalation schemes for combination therapies, which could affect the efficacy and tolerability balance.
- Zealand Pharma AS (ZLDPF) acknowledges the dynamic and competitive nature of the obesity market, which could impact the commercial success of its pipeline assets.
Good day and thank you for standing by. Welcome to the New Zealand Farmer Interim Report Q3 2025 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.
To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Adam Langer, Investor relations of Zealand Farmer. Please go ahead.
/- -
Thank you, operator, and thank you to everyone for joining us today to discuss Seland Farmers's results for the 1st 9 months of 2025.
You can find the related company announcement on our website at cnnfarmers.com.
As described on slide 2, we caution listeners that during this call, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
